Understanding the Phenotypic Heterogeneity Within the Sporadic Creutzfeldt-Jakob Disease MV1 Subtype

Satish K Nemani1,2, Leonardo M Cortez1,2, Jennifer Myskiw3

  • 1Centre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, Canada.

Insights

The MV1 subtype of sporadic Creutzfeldt-Jakob disease (sCJD) is more diverse than previously thought, showing varied prion protein (PrPD) patterns. Accurate sCJD subtyping requires pH 6.9 analysis to capture atypical and mixed cases.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Genetics

Background:

  • Sporadic Creutzfeldt-Jakob disease (sCJD) classification relies on PRNP codon 129 polymorphism and PrPD immunoblot type.
  • The MV1 sCJD subtype, characterized by methionine/valine (MV) polymorphism and type 1 PrPD, has been historically grouped with MM1.
  • Recent findings suggest MV1 cases exhibit heterogeneity, with some resembling the VV1 subtype, challenging the established classification.

Purpose of the Study:

  • To investigate the heterogeneity of the MV1 subtype of sporadic Creutzfeldt-Jakob disease (sCJD).
  • To characterize atypical MV1 cases with distinct prion protein (PrPD) fragment profiles and neuropathological features.
  • To evaluate the utility of asymmetric-flow field-flow fractionation in discriminating sCJD subtypes.

Main Methods:

  • Analysis of three MV1 sCJD cases with detailed immunoblotting of PrPD at pH 6.9 and pH 8.0.
  • Neuropathological examination including vacuolation patterns and PrPD deposition.
  • Application of asymmetric-flow field-flow fractionation to analyze PrPD size distributions.

Main Results:

  • All three MV1 cases exhibited atypical PrPD profiles with persistent T20 fragments, detectable only at pH 6.9.
  • Cases displayed mixed MM1/VV1 features, predominant VV1-like characteristics, or MV2C-like pathology, indicating significant heterogeneity.
  • Asymmetric-flow field-flow fractionation demonstrated potential for differentiating sCJD subtypes based on PrPD size.

Conclusions:

  • The MV1 sCJD subtype is more heterogeneous than previously recognized, potentially existing on a spectrum from MM1-like to VV1-like phenotypes.
  • Prion protein (PrPD) subtyping at pH 6.9 is crucial for identifying atypical and mixed sCJD cases, which may be missed at pH 8.0.
  • Further research into MV1 heterogeneity and the application of novel techniques like AF4-FFF could refine sCJD classification and understanding.

Related Concept Videos

Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
166
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
143
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
69
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
42